What's breaking now, across thousands of outlets.
It offers a "safe way to target chemo resistant tumors," the study's author Ozgur Sahin told Newsweek.
We haven't written up this one. Newsweek has the full story — the link below goes straight to it.
We deal with a seemingly endless conveyor belt of fad quack remedies (the proverbial game of whack-a-mole). We always have some new nonsense to deal with.
More than half of girls participating in the long-term U.S. Adolescent Brain Cognitive Development (ABCD) study developed painful periods (dysmenorrhea) by age 12 or 13, according to new research…
Roche licenses a tri-specific antibody, new Trump deals may undercut its own goals, and other biotech news
Daniel Chojnowski, JHHP’s current CFO, will provide stability so that the Baltimore-area insurer can recruit full-time for its next chief executive, the company said.
Marlboro-maker Altria is seeking to force the FDA to overhaul a review process it says has blocked newer nicotine products from reaching the market.
Ahead of respiratory illness season, professional organizations have issued guidance on flu, Covid, and RSV vaccines.
